Welcome to our dedicated page for Camp4 Therapeutics SEC filings (Ticker: CAMP), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The CAMP4 Therapeutics Corporation (Nasdaq: CAMP) SEC filings page on Stock Titan provides access to the company’s U.S. Securities and Exchange Commission disclosures, including current reports on Form 8-K and other registered offerings. CAMP4 identifies itself in these filings as a clinical-stage biopharmaceutical company developing regulatory RNA-targeting therapeutics and antisense oligonucleotide (ASO) drug candidates to upregulate gene expression for genetic diseases.
Through its Form 8-K filings, CAMP4 reports material events such as securities purchase agreements, private placements, and underwritten offerings of common stock registered on Form S-3. These filings describe how the company expects to use proceeds to support preclinical and clinical development of product candidates, including its SYNGAP1 program, and to fund working capital and general corporate purposes.
CAMP4’s 8-K filings also detail strategic collaboration agreements, including a research, collaboration and license agreement with GSK covering antisense oligonucleotide therapeutics targeting regulatory RNAs for neurodegenerative and kidney disease indications. The filings outline key terms such as exclusive worldwide licenses under certain patents and know-how, upfront payments, potential development and commercial milestones, and tiered royalties on net sales.
Additional 8-Ks address corporate governance and compensation matters, including changes to the board of directors, inducement equity grants under Nasdaq Listing Rule 5635(c)(4), and registration rights agreements associated with private placements. As an emerging growth company, CAMP4 uses these reports to communicate significant operational, financing, and collaboration developments.
On Stock Titan, investors can review CAMP4’s filings alongside AI-powered summaries that explain the significance of each document. Users can quickly see highlights from annual and quarterly reports when available, track current reports on Form 8-K, and monitor equity financing terms, collaboration structures, and other regulatory disclosures relevant to CAMP4’s RNA-targeting therapeutic pipeline.
CAMP4 Therapeutics Corporation is holding its 2026 annual stockholder meeting as a virtual-only webcast on June 10, 2026, at 11:00 a.m. Eastern. Stockholders will vote on electing three Class II directors, ratifying Ernst & Young LLP as auditor, and approving an amendment to the 2024 Equity Incentive Plan.
The record date is April 13, 2026, with 51,925,800 common shares entitled to one vote each. The proxy statement outlines board structure, committee responsibilities, executive and director pay, and severance and change-in-control protections for senior leaders.
Camp4 Therapeutics Corp Chief Scientific Officer Daniel Tardiff received a grant of stock options covering 170,000 shares of common stock. The options have an exercise price of $4.46 per share and expire on March 31, 2036.
The options vest in equal monthly installments over four years starting from the grant date, aligning compensation with long-term company performance. Following this award, Tardiff holds 170,000 stock options directly, reflecting a routine, compensation-related equity grant rather than an open-market trade.
Camp4 Therapeutics reported that Chief Medical Officer Yuri Maricich received a grant of stock options covering 215,000 shares of common stock. The options have an exercise price of $4.46 per share, expire on March 31, 2036, and vest in equal monthly installments over four years from the grant date.
Camp4 Therapeutics Corp Chief Financial Officer Kelly Gold received a grant of stock options covering 215,000 shares of common stock. The options have an exercise price of $4.46 per share and expire in 2036.
The shares underlying the option vest in equal monthly installments over four years from the grant date, meaning the award functions as long-term, time-based compensation rather than an immediate cash transaction.
Camp4 Therapeutics Corp reported that Chief Executive Officer Josh Mandel-Brehm received a grant of stock options on Common Stock. The award covers 580,000 shares with an exercise price of $4.46 per share and an expiration date of March 31, 2036.
The options vest in equal monthly installments over four years starting from the grant date, meaning the award is earned gradually over time. Following this grant, Mandel-Brehm holds stock options covering 580,000 shares directly.
Camp4 Therapeutics director Michael F. MacLean received a new stock option award for 56,000 shares of common stock. The option has an exercise price of $4.46 per share and expires on March 31, 2036. This is a compensation-related grant, not an open-market purchase.
The option covers 56,000 underlying shares and was awarded at no cost on the grant date. The shares underlying the option vest in equal monthly installments over three years starting from the grant date, so MacLean earns the right to exercise portions of the award gradually over time.
Camp4 Therapeutics Corp director Michael F. MacLean filed an initial Form 3, which is the required statement of beneficial ownership when someone becomes an insider. This filing lists him as a director but does not report any buy or sell transactions in the company’s securities.
CAMP4 Therapeutics Corporation announced that its Board of Directors has appointed Michael MacLean as a Class III director, effective April 1, 2026, and expanded the Board from eight to nine members. He will also join the Audit Committee and Compensation Committee.
MacLean brings more than 35 years of financial leadership in biotechnology and life sciences, including serving as Chief Financial Officer of Avidity Biosciences through its IPO and subsequent acquisition by Novartis, and prior senior roles at Akcea Therapeutics, PureTech Health, and Biogen. Under an amended non-employee director compensation policy, he will receive an option to purchase 56,000 shares of CAMP4 common stock, vesting in monthly installments over three years, plus standard cash retainers and the company’s standard director indemnification agreement.
Enavate Sciences entities filed Amendment No. 3 to report that they beneficially own 2,495,562 shares of CAMP4 Therapeutics common stock, representing 4.8% of the class based on 51,919,321 shares outstanding as of March 4, 2026. Everest LP holds the shares directly, and Enavate Sciences GP, LLC, as general partner, shares voting and investment power. The reporting persons state they ceased to be beneficial owners of more than five percent of the common stock on March 9, 2026. In the prior sixty days, Everest LP sold multiple blocks of shares in open-market trades, including 91,699 shares on March 9, 2026 at a weighted average price of $6.69 per share and 99,639 shares on March 10, 2026 at a weighted average price of $5.83 per share.